Focal Segmental Glomerulosclerosis
Focal segmental glomerulosclerosis (FSGS) is a rare kidney disease characterized by scarring in the glomeruli, leading to proteinuria (excess protein in urine) and potential kidney failure.
Focal Segmental Glomerulosclerosis: DMX-200 Treatment Study
We are studying the effects of DMX-200 on kidney function in patients with focal segmental glomerulosclerosis who are taking an angiotensin II receptor blocker. This trial will help us understand its safety and effectiveness compared to standard treatments.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you between 18 and 75 years old?
- Do you have a history of uncontrolled diabetes (blood sugar problems) with a hemoglobin A1c greater than 8%?
- Are you currently taking corticosteroids like prednisone at a dose of 10 mg or less per day?
- Have you had any major heart problems or events in the last 12 weeks?
- Is your estimated kidney function (eGFR) 25 mL/min/1.73 m2 or higher?
What experimental substances are being tested?
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Repagermanium
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Vseobecna Fakultni Nemocnice V Praze
Klinika nefrologie
Prague, Czechia
Odense University Hospital
Department of Nephrology
Århus, Denmark
Rigshospitalet
Dept of Nephrology
Copenhagen, Denmark
Sponsor: Dimerix Bioscience Pty Limited
Last updated: Nov 27, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.